Dr. Robert T. Naismith, MD

Dr. Naismith practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Naismith's NPI, 1871519090, was assigned on July 14, 2006. Dr. Naismith holds Missouri license 2000146127.

Dr. Naismith's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Naismith also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Naismith's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Naismith is also affiliated with Missouri Baptist Medical Center. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Naismith to 3 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Naismith practices, 6 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Naismith's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Naismith is licensed in Missouri.

CMS data shows 125 Medicare services from Dr. Naismith across 3 procedure codes in 2024, for 79 Medicare patients. Medicare paid $8,711 for them.

CMS counts 79 Medicare patients who saw Dr. Naismith in 2024. The largest group is 65 to 74, with 34 patients. 67% of them have high blood pressure, and 57% have high cholesterol. 35% are also on Medicaid. Their average risk score is 1.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Naismith's median patient age at 55, with 74% women.

In 2024, Dr. Naismith wrote 1,282 Medicare Part D claims for 107 patients. 82% of them were for generic drugs. CMS names the drug for 1,048 of them, across 37 drugs with 11 or more claims each, at $2,233,905 in total drug cost. In 2023, CMS named 1,092 claims across 39 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Naismith for performance year 2024, reported as part of a group. Dr. Naismith accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Naismith to 1 clinical trial. Conditions studied include Multiple Sclerosis, Relapsing-Remitting and Multiple Sclerosis. Open Payments lists research payments to Dr. Naismith that name 1 trial.

CMS Open Payments shows 809 general payments to Dr. Naismith from 30 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 55% of the total. Sanofi and Genzyme US Companies paid the most, $393,320. It also lists 61 research payments totaling $37,861 from 2017 to 2025, naming 1 clinical trial.